Eddie Albers
US Life Sciences Practice Leader
-
United States
As the pharmaceutical industry — including biopharma, specialty drugs, generics, animal health, and nutraceuticals — continues to evolve and change, the risks faced by these businesses are becoming increasingly complex and interconnected.
The full impact of the COVID-19 pandemic will take time to be realized. But the current environment has put a spotlight on a number of trends that can pose risks to pharmaceutical companies, including:
As pharmaceutical companies continue their recovery process, it is more critical than ever to have a risk management strategy in place to address emerging trends and protect fundamental operations.
Marsh’s risk advisors have vast experience working with companies like yours and can help you design, develop, and implement risk management strategies tailored to your unique needs.
Report
01/10/2024
Pharmaceutical companies share much of the same risks as in other industries, from banking and finance to energy companies. For this reason, it can be helpful to look both inside and outside of the industry for risk management approaches including:
Our team of industry specialists have insight into the risks faced by companies within and outside the pharmaceutical industry. We can help you identify your most pressing risks, quantify them, and develop a custom mitigation and risk transfer plan.
US Life Sciences Practice Leader
United States